Security assessments indicated that gastrointestinal adverse occasions, mainly nausea and diarrhea, had been dose-dependent but frequently moderate and transient. These results established the therapeutic window and educated dose variety for subsequent Phase 3 trials.第一步：请输入基本实验信息（考虑到实验过程中的损耗，建�